Company News: ISA Pharmaceuticals Appoints Gerben Moolhuizen as Chief Business Development Officer
– Seasoned executive brings over twenty years of commercial biotech and pharma experience
ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced that Gerben Moolhuizen has been appointed as the company´s Chief Business Development Officer (CBO).
Gerben Moolhuizen has over twenty years of experience in the pharmaceutical and biotechnology industry in various roles covering business development, product development and general management. His experience spans very diverse fields covering a broad array of technical areas (biopharmaceuticals, small molecules, drug delivery, pharmaceutical development and manufacturing, diagnostics, vaccines, generics). Gerben Moolhuizen joins ISA Pharmaceuticals from OctoPlus, where his most recent role was General Manager. He has been closely involved in the company´s fundraising activities, IPO, and the acquisition by Dr. Reddy’s. and has also been responsible for the subsequent integration of OctoPlus into Dr. Reddy’s R&D organization. Prior to OctoPlus, Gerben Moolhuizen worked, among others, at Pharming, where he held various roles in business development and product development and was also involved in the company´s IPO in 1998 . He holds an M.Sc. from Utrecht University in Medical Biology and an MBA from Erasmus University Rotterdam.